Collaborative efforts driving progress in pediatric acute myeloid leukemia
CM Zwaan, EA Kolb, D Reinhardt… - Journal of clinical …, 2015 - ascopubs.org
Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …
leukemia (AML) have made enormous progress during the past decades. Because AML is a …
[HTML][HTML] Hematopoietic cell transplantation in the treatment of pediatric acute myelogenous leukemia and myelodysplastic syndromes: guidelines from the American …
K Tarlock, ML Sulis, JH Chewning, JA Pollard… - … and Cellular Therapy, 2022 - Elsevier
The role of allogeneic hematopoietic stem cell transplantation (HCT) in the treatment of
acute myelogenous leukemia (AML) in children is reviewed and critically evaluated in this …
acute myelogenous leukemia (AML) in children is reviewed and critically evaluated in this …
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant
JJ Bednarski, C Zimmerman… - Blood, The Journal …, 2022 - ashpublications.org
Pediatric and young adult (YA) patients with acute myeloid leukemia (AML) who relapse
after allogeneic hematopoietic cell transplantation (HCT) have an extremely poor prognosis …
after allogeneic hematopoietic cell transplantation (HCT) have an extremely poor prognosis …
[HTML][HTML] Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
I Christodoulou, WJ Ho, A Marple… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background The prognosis of patients with recurrent/refractory acute myelogenous leukemia
(AML) remains poor and cell-based immunotherapies hold promise to improve outcomes …
(AML) remains poor and cell-based immunotherapies hold promise to improve outcomes …
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group
GJL Kaspers, M Zimmermann, D Reinhardt… - Journal of Clinical …, 2013 - ascopubs.org
Purpose In pediatric relapsed acute myeloid leukemia (AML), optimal reinduction therapy is
unknown. Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen …
unknown. Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen …
T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy
C Horgan, K Mullanfiroze, A Rauthan, K Patrick… - Blood …, 2023 - ashpublications.org
Stem cell transplant (SCT) outcomes in high-risk and relapsed/refractory (R/R) pediatric
acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been historically …
acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been historically …
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma …
L Pommert, ES Schafer, J Malvar… - American journal of …, 2022 - Wiley Online Library
Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML)
remain dismal. Epigenetic changes can result in gene expression alterations which are …
remain dismal. Epigenetic changes can result in gene expression alterations which are …
Acute myeloid leukemia in children: Current status and future directions
T Taga, D Tomizawa, H Takahashi… - Pediatrics …, 2016 - Wiley Online Library
Acute myeloid leukemia (AML) accounts for 25% of pediatric leukemia and affects
approximately 180 patients annually in Japan. The treatment outcome for pediatric AML has …
approximately 180 patients annually in Japan. The treatment outcome for pediatric AML has …
[HTML][HTML] Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023
Although outcomes of children and adolescents with newly diagnosed acute myeloid
leukemia (AML) have improved significantly over the past two decades, more than one-third …
leukemia (AML) have improved significantly over the past two decades, more than one-third …
Venetoclax for acute myeloid leukemia in pediatric patients: a Texas Medical Center experience
Simple Summary Pediatric patients with relapsed or refractory acute myeloid leukemia
(AML) have poor survival with current therapy. Venetoclax is a small molecule inhibitor that …
(AML) have poor survival with current therapy. Venetoclax is a small molecule inhibitor that …